research Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
Search
for
Sort by
Research
600-630 / 1000+ results 
research Enzalutamide, a prostate cancer therapeutic, downregulates TMPRSS2 in lung and reduces cellular entry of SARS-CoV-2
Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
research 1116 Novel androgen receptor degrader for androgenetic alopecia (AGA) application
A new treatment for hair loss shows promise with fewer side effects.
research O que sabemos sobre os inibidores da 5 alfa redutase?
Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
research Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy
Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.
research Approved systemic drugs needed for dermatosis like alopecia areata, hidradenitis and vitiligo: A SPIN ‐FRT evaluation
More effective treatments are needed for alopecia areata, hidradenitis suppurativa, and vitiligo.
research Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study
Men taking dutasteride may have a higher risk of age-related macular degeneration.
research Retinoic acids shift skin stem cell fate
Retinoic acids temporarily change skin stem cells to a slower cycle and more differentiated state.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research New ester derivatives of dehydroepiandrosterone as 5α-reductase inhibitors
New compounds may help treat prostate issues without affecting androgen receptors.
research Retinoids in Dermatology
Retinoids are effective for severe acne and psoriasis but can cause serious side effects and birth defects.
research Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
5α-Reductase inhibitors may increase depression risk but not dementia or suicide.
research 5‐alpha‐reductase inhibitor treatment for frontal fibrosing alopecia: an evidence‐based treatment update
5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.
research How useful is ritlecitinib in alopecia areata?
Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
research Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis
Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.
research Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
research Review: Adding α1-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
research Efficient Silencing of Androgen Receptor Gene via UTR-Targeting siRNAs for Androgenetic Alopecia Therapy
AR-27 E-Chol siRNA can effectively regrow hair by reducing androgen receptor gene activity.
research Design, synthesis and structure-activity relationships studies on steroidal aromatase and 5α-reductase inhibitors as anti-tumors
Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
research Editorial: Retinoids — dermatologists’ drug of the decade
Retinoids are important for treating skin conditions but should be used with caution due to serious side effects and risks during pregnancy.
research The clinical applications of five-alpha reductase inhibitors.
Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
research Lifestyle drugs: concept and impact on society
Lifestyle drugs are mainly used by wealthy people in India but could spread to others, affecting society and youth.
research Effects of adenosine triphosphate on vandetanib induced skin damage in rats
ATP helps prevent skin damage from vandetanib by reducing stress.
research How useful is ritlecitinib in alopecia areata?
Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
research THE ROLE Of 5αR AND α1AR INHIBITORS IN MANAGEMENT OF BPH
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
research Alopecia areata and ritlecitinib: Unravelling response trajectories
Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
research Why Odds Ratios Can Be Tricky Statistics
Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.